Prostate Cancer Screening: a Pilot Study

Launched by FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA · Jan 25, 2024

Keywords

ClinConnect Summary

Men aged 55-65 years with neither previous biopsy nor prostate diseases will be invited in the screening protocol and will perform an initial PSA test. Those cases with PSA ≥ 3 ng/ml will be invited to undergo a urologic examination with computed risk assessment and an MRI, which is a non-invasive test with high positive and negative predictive value in identifying clinically significant prostate cancer. Then, only men with medium-high risk of harbouring clinically significant prostate cancer will be invited to undergo a prostate biopsy to indentify cancer presence and its aggressiveness.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • age between 55-65 years;
• • asymptomatic or paucisymptomatic from a urological point of view;
• • no previous prostate biopsy;
• • living in the ASL TO5 (Piedmont, Italy);
• • signed written informed consent.
• Exclusion Criteria:
• • positive oncologic anamnesis for prostate cancer;
• • previous biopsy or prostate surgery;
• • previous radiotherapy of the pelvis;
• • any contraindication to MRI examination;
• • claustrophobic or uncollaborative subjects.